BiotechTube

APL-130277 + subcutaneous apomorphine

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Motor OFF Episodes Associated With Parkinson's Disease

Conditions

Motor OFF Episodes Associated With Parkinson's Disease

Trial Timeline

Dec 19, 2018 → Aug 11, 2021

NCT ID
NCT03391882

About APL-130277 + subcutaneous apomorphine

APL-130277 + subcutaneous apomorphine is a phase 3 stage product being developed by Sumitomo Pharma for Motor OFF Episodes Associated With Parkinson's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03391882. Target conditions include Motor OFF Episodes Associated With Parkinson's Disease.

What happened to similar drugs?

2 of 17 similar drugs in Motor OFF Episodes Associated With Parkinson's Disease were approved

Approved (2) Terminated (0) Active (15)
🔄fezolinetant + placeboAstellas PharmaPhase 3
✅17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
🔄DVS-233 SRPfizerPhase 3
🔄Bazedoxifene/Conjugated EstrogenPfizerPhase 3
🔄desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
🔄desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
🔄Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03391882Phase 3Completed

Competing Products

20 competing products in Motor OFF Episodes Associated With Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
fezolinetant + placeboAstellas PharmaPhase 3
40
Ranirestat + PlaceboEisaiPhase 2/3
38
Raloxifene + medroxyprogesterone acetate + estrogen + 17 beta estradiolEli LillyPhase 2
35
esomeprazole + placeboAstraZenecaPre-clinical
26
MK-6913 + 17-β estradiol + Placebo to MK-6913 + Placebo to 17-β estradiol + MK-6913 25 mgMerckPhase 2
27
Erenumab + PlaceboAmgenPhase 1
29
17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle) + Tibolone (Livial)PfizerApproved
43
DVS-233 SRPfizerPhase 3
40
1 mg QD to 15 mg QD PF-06649751 + 3 mg QD to 15 mg QD PF-06649751 + 7 mg QD to 15 mg QD PF-06649751 + 15 mg QD PF-06649751 + 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) + 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QDPfizerPhase 2
27
Bazedoxifene/Conjugated EstrogenPfizerPhase 3
40
desvenlafaxine succinate sustained release (DVS SR)PfizerPhase 1
29
desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + Placebo + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained release + desvenlafaxine succinate sustained releasePfizerPhase 3
40
desvenlafaxine succinate (DVS) SR + PlaceboPfizerPhase 3
40
VivaglobinCSLPhase 2
35
LevetiracetamUCBPhase 2
35
ARGX-117ArgenxPhase 2
36
Empasiprubart + IVIG (Intravenous Immunoglobulin)ArgenxPhase 3
44
ARGX-117ArgenxPhase 2
32
Treatment A + Treatment B + Treatment CBayerPhase 1
26
Elinzanetant (BAY3427080) + PlaceboBayerPhase 1
26